GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Biogen Idec Inc (BIIB) [hlAlert]

Rating:
Buy BIIB
up 534.61 %

Biogen Idec Inc (BIIB) rated Buy with price target $56 by Lazard Capital

Posted on: Thursday,  Sep 25, 2008  8:25 AM ET by Lazard Capital

Lazard Capital rated Buy Biogen Idec Inc (NASDAQ: BIIB) on 09/25/2008, when the stock price was $47.98. Since
then, Biogen Idec Inc has gained 534.62% as of 01/07/2016's recent price of $304.49.
If you would have followed this Lazard Capital's recommendation on BIIB, you would have gained 534.61% of your investment in 2660 days.

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company?s products address diseases such as multiple sclerosis, non-Hodgkin?s lymphoma (NHL), rheumatoid arthritis (RA), crohn?s disease (CD) and psoriasis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is one of the selling oncology therapeutics. In the United States, RITUXAN is approved for NHL. TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. The Company also has product candidates, such as BG-12, which is a oral fumarate; ANTI-CD80 monoclonal antibody (MAb)(galiximab); ANTI-CD23 MAb (lumiliximab); Humanized Anti-CD20 MAb (ocrelizumab), Lixivaptan, an oral compound for the potential treatment of hyponatremia, and ADENTRI.

Lazard Capital Markets’ research team is broadly recognized for its insight, thoroughness, and objectivity. Our goal is to help our clients make the best-informed decisions by providing timely, thoughtful analysis as well as access to company management teams and industry thought leaders. Our industry-focused analysts strive to identify emerging sector trends as well as bottom-up fundamental issues affecting their stocks under coverage. We add value by conducting extensive primary survey work, hosting proprietary events, cultivating industry contacts, and participating in relevant industry conferences.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/25/2008 8:25 AM Buy
None
47.98 56.00
as of 12/24/2008
1 Week down  -8.00 %
1 Month down  -9.64 %
3 Months down  -3.25 %
1 YTD down  -3.25 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy